Jamie Scism‐Bacon

752 total citations
14 papers, 606 citations indexed

About

Jamie Scism‐Bacon is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Molecular Biology. According to data from OpenAlex, Jamie Scism‐Bacon has authored 14 papers receiving a total of 606 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Endocrinology, Diabetes and Metabolism, 4 papers in Surgery and 4 papers in Molecular Biology. Recurrent topics in Jamie Scism‐Bacon's work include Diabetes Treatment and Management (12 papers), Diabetes Management and Research (11 papers) and Metabolism, Diabetes, and Cancer (4 papers). Jamie Scism‐Bacon is often cited by papers focused on Diabetes Treatment and Management (12 papers), Diabetes Management and Research (11 papers) and Metabolism, Diabetes, and Cancer (4 papers). Jamie Scism‐Bacon collaborates with scholars based in United States, Netherlands and Belgium. Jamie Scism‐Bacon's co-authors include Honghua Jiang, Sherry Martin, Andrew Ahmann, Julio Rosenstock, Anthony J. Zagar, Jessie L. Fahrbach, Scott J. Jacober, Jeffrey A. Jackson, Bruce H. R. Wolffenbuttel and William H. Herman and has published in prestigious journals such as SHILAP Revista de lepidopterología, Diabetes Care and Journal of Bone and Mineral Research.

In The Last Decade

Jamie Scism‐Bacon

13 papers receiving 578 citations

Peers

Countries citing papers authored by Jamie Scism‐Bacon

Since Specialization

Citations

This map shows the geographic impact of Jamie Scism‐Bacon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jamie Scism‐Bacon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jamie Scism‐Bacon more than expected).

Fields of papers citing papers by Jamie Scism‐Bacon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jamie Scism‐Bacon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jamie Scism‐Bacon. The network helps show where Jamie Scism‐Bacon may publish in the future.

Co-authorship network of co-authors of Jamie Scism‐Bacon

This figure shows the co-authorship network connecting the top 25 collaborators of Jamie Scism‐Bacon. A scholar is included among the top collaborators of Jamie Scism‐Bacon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jamie Scism‐Bacon. Jamie Scism‐Bacon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

#	Work	Indexed citations
1	DURAbility of Basal Versus Lispro Mix 75/25 Insulin Efficacy (DURABLE) Trial 24-Week Results: Safety and efficacy of insulin lispro mix 75/25 versus insulin glargine added to oral antihyperglycemic drugs in patients with type 2 diabetes 2020 ·UNC Libraries ·(unknown), (unknown), (unknown), Jamie Scism‐Bacon, (unknown), Bruce H. R. Wolffenbuttel, (unknown), (unknown)	0
2	The Risk of Severe Hypoglycemia in Patients with Type 2 Diabetes Mellitus Starting Insulin Therapy with Premixed Insulin Analogues Taken Twice Daily: An Observational Study in Turkish Patients 2013 ·SHILAP Revista de lepidopterología ·(unknown), Mustafa Sait Gönen, (unknown), Esma Altunoğlu, (unknown), Jamie Scism‐Bacon, (unknown), (unknown)	1
3	1.2 Efficacy and Safety of Dulaglutide versus Placebo and Exenatide in Type 2 Diabetes (AWARD-1) (66-OR) 2013 ·Carol Wysham, Thomas Blevins, Richard F. Arakaki, (unknown), Pedro García, Charles Atisso, (unknown), Jamie Scism‐Bacon, Mark Lakshmanan	1
4	Efficacy and Safety of Dulaglutide Versus Placebo and Exenatide in Type 2 Diabetes (AWARD-1) 2013 ·Canadian Journal of Diabetes ·Carol Wysham, Thomas Blevins, Richard F. Arakaki, (unknown), Pedro García, Charles Atisso, (unknown), Jamie Scism‐Bacon, Mark Lakshmanan	6
5	Safety of exenatide once weekly for 52 weeks in Japanese patients with type 2 diabetes mellitus 2012 ·Journal of Diabetes Investigation ·Yukiko Onishi, Hiroyuki Koshiyama, Takeshi Imaoka, Harry Haber, Jamie Scism‐Bacon, Marilyn K. Boardman	11
6	Safety and Efficacy of Once-Weekly Exenatide Compared With Insulin Glargine Titrated to Target in Patients With Type 2 Diabetes Over 84 Weeks 2012 ·Diabetes Care ·Michaëla Diamant, Luc Van Gaal, Stephen Stranks, Bruno Guerci, Leigh MacConell, Harry Haber, Jamie Scism‐Bacon, Michael Trautmann	79
7	Exenatide bid observational study (ExOS): baseline population characteristics of a prospective research study to evaluate the clinical effectiveness of exenatide bid use in patients with type 2 diabetes in a real-world setting 2011 ·Current Medical Research and Opinion ·Richard M. Bergenstal, Louis P. Garrison, Matthew Wintle, (unknown), Rolin L. Wade, (unknown), (unknown), Jamie Scism‐Bacon, Anthony J. Zagar, Derek Misurski, William H. Herman	4
8	Impact of Race/Ethnicity on the Efficacy and Safety of Commonly used Insulin Regimens: A Post HOC Analysis of Clinical Trials in Type 2 Diabetes Mellitus 2010 ·Endocrine Practice ·Jaime A. Davidson, (unknown), Honghua Jiang, Cory R. Heilmann, Jamie Scism‐Bacon, (unknown), Jeffrey A. Jackson	24
9	Randomized, open-label, parallel-group evaluations of basal-bolus therapy versus insulin lispro premixed therapy in patients with type 2 diabetes mellitus failing to achieve control with starter insulin treatment and continuing oral antihyperglycemic drugs: A noninferiority intensification substudy of the DURABLE trial 2010 ·Clinical Therapeutics ·William F. Miser, Richard F. Arakaki, Honghua Jiang, Jamie Scism‐Bacon, Pamela W. Anderson, Jessie L. Fahrbach	34
10	High-dose Insulin Therapy: is it Time for U-500 Insulin? 2009 ·Endocrine Practice ·Wendy Lane, Elaine Cochran, Jeffrey A. Jackson, Jamie Scism‐Bacon, (unknown), Irl B. Hirsch, Jay S. Skyler	94
11	DURAbility of Basal Versus Lispro Mix 75/25 Insulin Efficacy (DURABLE) Trial 24-Week Results 2009 ·Diabetes Care ·John B. Buse, Bruce H. R. Wolffenbuttel, William H. Herman, (unknown), Honghua Jiang, Jessie L. Fahrbach, Jamie Scism‐Bacon, Sherry Martin	109
12	Advancing Insulin Therapy in Type 2 Diabetes Previously Treated With Glargine Plus Oral Agents 2007 ·Diabetes Care ·Julio Rosenstock, Andrew Ahmann, (unknown), Jamie Scism‐Bacon, Honghua Jiang, Sherry Martin	162
13	Effect of Growth Hormone Replacement on BMD in Adult-Onset Growth Hormone Deficiency 2007 ·Journal of Bone and Mineral Research ·Peter J. Snyder, Beverly M. K. Biller, Anthony J. Zagar, Ivor M.D. Jackson, Baha M. Arafah, Todd B. Nippoldt, David M. Cook, Arshag D. Mooradian, Anita Y. M. Kwan, Jamie Scism‐Bacon, John J. Chipman, Mark L. Hartman	28
14	A comparison of intensive mixture therapy with basal insulin therapy in insulin‐naïve patients with type 2 diabetes receiving oral antidiabetes agents 2006 ·Diabetes Obesity and Metabolism ·Scott J. Jacober, Jamie Scism‐Bacon, Anthony J. Zagar	53

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact